ACCESS Newswire

Cactus Life Sciences

24.4.2024 15:48:41 CEST | ACCESS Newswire | Press release

Share
nspm and eluSCIdate Have Now Joined Cactus Life Sciences Bringing With Them Extensive Rare Disease Expertise

Cactus Life Sciences has begun their exciting buy-and-build strategy adding key services to their portfolio

PRINCETON, NJ / ACCESSWIRE / April 24, 2024 / Cactus Life Sciences, a leading global scientific communications agency that works with blue chip pharma and biotechnology companies, announced today that they have acquired nspm and eluSCIdate, two dynamic medical communications and publications companies headquartered in Meggen, Switzerland with an office in the UK.

To view this piece of content from cdn.nwe.io, please give your consent at the top of this page.
Integration of nspm and eluSCIdate
logo lockup

Cactus Life Sciences, headquartered in Princeton, New Jersey, was formed in 2010 and is best known for its transformational global operating models that provide best in class science, innovation, and efficiency. Founded 27 years ago, nspm brings extensive expertise in medical communications, publications, and event management, with a focus on rare diseases. Its sister company eluSCIdate was founded in 2020 and focuses on medical and scientific publications, combining extensive experience in medical writing with creative flair to deliver high-quality publications.

This collaboration signifies a major step forward in enhancing services for our biopharma clients, ensuring a comprehensive and fully integrated global approach to medical communications. And provides a significant employee footprint in US, UK, Switzerland, and Japan.

"As Cactus Life Sciences embarks on its forthcoming buy-and-build strategy, we're excited to unveil our first acquisition that shares so many of the same values as CACTUS, stated Oliver Dennis, the new Chairman of Cactus Life Sciences. "As we move forward, we seek partnerships that prioritize our people and clients alongside our strategic growth."

Rare diseases individually affect a small number of people, but collectively affect over 300 million worldwide, presenting significant challenges for patients and medical professionals. nspm's rare disease expertise addresses unmet needs for patients and society. Sabine Stotz, PhD, Managing Director, nspm, noted "This strategic alliance is a testament to the shared vision of excellence between Cactus Life Sciences, nspm and eluSCIdate. Together, our goal is to enrich the global landscape of scientific communications creating an even greater impact on healthcare professionals and the patients they treat".

Elvira Dsouza, President, Cactus Life Sciences remarked, "Cactus Life Sciences stands out for its unwavering commitment to excellence, innovation, and future readiness. With a focus on integrating cutting-edge technology, notably AI, we aim to elevate scientific content creation to contribute to a more accessible, informed, and transformative healthcare landscape".

About Cactus Life Sciences (cactuslifesciences.com): Cactus Life Sciences is a medical communication company that provides scientific strategy and content across the healthcare continuum, anywhere in the world ─ with a focus on science, innovation, and efficiency. We work alongside leading healthcare companies to establish the optimal role of medicines and encourage positive behaviors (physician and patient) that improve patient outcomes.

About nspm (www.nspm.com): nspm is a successful and dynamic medical communications company founded in 1997 with offices in Switzerland and the UK. nspm provides a complete range of medical writing, project management, and strategic medical communications solutions for the pharmaceutical and biotech industry across a range of therapeutic areas, with a focus on rare diseases. Our employees are committed to crafting high-quality, cost-effective solutions that exceed clients' expectations through scientific excellence, professionalism, and creativity.

About eluSCIdate (www.eluscidate.com): eluSCIdate is a medical writing agency founded in 2020 that specializes in scientific publications, providing support for the entire publication process. We use a wealth of experience in medical writing to deliver high-quality manuscripts, posters, and slides to our clients. At eluSCIdate, we are passionate about science and committed to providing clarity in scientific messaging. Through effective communication, we work with our clients to ensure their science stands out from the crowd.

Contact Information:

Laura Perry
VP of Strategy and Marketing
inquiries@cactuslifesciences.com
7327121005

SOURCE: Cactus Life Sciences

To view this piece of content from stats.nwe.io, please give your consent at the top of this page.

View the original press release on newswire.com.

To view this piece of content from www.accesswire.com, please give your consent at the top of this page.

About ACCESS Newswire

DK

Subscribe to releases from ACCESS Newswire

Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from ACCESS Newswire

QorusDocs Named LegalTech AI Platform of the Year and Ranked No. 1 Proposal Management Software17.11.2026 15:00:00 CET | Press release

BELLEVUE, WA / ACCESS Newswire / November 17, 2026 / QorusDocs, the pursuit intelligence platform trusted by dozens of Am Law 200 and Global 200 law firms, today announced it has been named LegalTech AI Platform of the Year in the seventh annual LegalTech Breakthrough Awards program and ranked the No. 1 proposal management solution by Info-Tech Research Group's SoftwareReviews, based on verified end-user reviews. The recognitions cap a year of rapid growth in legal for QorusDocs, which forecasts it will double its annual recurring revenue (ARR) from law firms in the next 12 months by adding more high-profile firms to its list of big law customers, which already includes DLA Piper, Baker McKenzie, Herbert Smith Freehills Kramer and Womble Bond Dickinson. Firms are moving AI beyond research and drafting and into business development, where a winning pitch depends on the best representative matters, strong attorney biographies and winning pitch strategies: knowledge general AI tools lack.

Freezz Italia Awarded ESA Contract for IRIS(2) Low-LEO Pre-Operational and De-Risk Activities17.11.2026 14:00:00 CET | Press release

CORTONA, IT / ACCESS Newswire / November 17, 2026 / Freezz Italia has been awarded a contract by the European Space Agency (ESA), as prime contractor leading a European industrial consortium, for the Consolidation Phase of the IRIS² Low-LEO Pre-Operational and De-Risk Activities, part of the ESA Programme Related to EU Secure Connectivity. The activity will further mature Friisat, Freezz's satellite system architecture conceived specifically for operation in Very Low Earth Orbit (VLEO) and designed for future broadband Direct-to-Device (D2D) connectivity within the 3GPP 5G/6G Non-Terrestrial Network (NTN) framework. Under this ESA contract, Freezz Italia will consolidate the mission and system architecture, adapting Friisat's existing commercial design to meet the requirements of an IRIS²-compatible solution, including future governmental broadband Direct-To-Device secure-connectivity services. The work will address the system and service concepts, architecture and interfaces, security

International Business Times UK Increases Programmatic Revenue by 30% with Opti Digital17.11.2026 11:00:00 CET | Press release

PARIS, FR / ACCESS Newswire / November 17, 2026 / Opti Digital, the leading AdTech company specialising in publisher revenue optimisation, today announced the results of its collaboration with International Business Times UK, an international digital news brand delivering business, markets, technology and current affairs coverage to a global readership. Operating in a fast-moving news environment, International Business Times UK continuously explores opportunities to increase the value of its digital audience while maintaining control over advertising quality and user experience. The publisher identified an opportunity to generate incremental revenue from its existing audience and inventory through a monetisation experience that could be tested progressively and scaled across a broader share of its inventory. "We were looking for ways to generate more value from our existing inventory, and the performance quickly demonstrated the potential of the new experience. It has become a meaning

OBI Pharma Signs Collaboration and License Agreement with Novartis16.11.2026 09:10:00 CET | Press release

TAIPEI, TW / ACCESS Newswire / November 16, 2026 / OBI Pharma, Inc. (4174.TWO) ("OBI") announced that it has entered into a Collaboration and License agreement with Novartis Pharma AG ("Novartis") to develop next generation Antibody-Drug-Conjugates (ADCs) with novel payloads, using OBI's suite of platform technologies. Under the terms of the agreement, Novartis will receive worldwide rights to OBI's related patents and know-how using its ADC platform technologies on an exclusive basis for selected, undisclosed Novartis payload classes. In parallel, under the collaboration OBI will evaluate novellinker approaches with the Novartis payloads. Novartis will further have the option to expand the agreement to include additional novel payload classes. This agreement marks an important milestone for OBI and underscores the value of its differentiated ADC technology platform. The agreement recognizes the potential of OBI's proprietary technologies, including GlycOBI®, EndoSymeOBI®, HYPrOBI®, an

Digi Power X Reports Q3 2026 Revenue Up 85% and AI Revenue Up Over 400% Compared to Q213.11.2026 13:30:00 CET | Press release

MIAMI, FL / ACCESS Newswire / November 13, 2026 / Digi Power X Inc. (Nasdaq:DGXX)(Cboe Canada:DGX) ("Digi Power X" or the "Company"), an AI data center infrastructure operator, today reported its financial and operating results for the third quarter ended September 30, 2026 (all amounts in U.S. dollars, unless otherwise indicated). The Company's quarterly report on Form 10-Q, which includes unaudited consolidated financial statements and management's discussion and analysis ("MD&A") for the quarter ended September 30, 2026, is being filed and made accessible under the Company's continuous disclosure profile on SEDAR+ at www.sedarplus.ca and will also be available on EDGAR at www.sec.gov/edgar. Third Quarter 2026 Highlights All amounts in U.S. dollars (millions) Revenue of $12.25 million, up 85% from the previously completed fiscal quarter and an increase of 50% compared to the quarter ended September 30, 2025; $119.6 million in cash, cash equivalents and digital currencies, $103.0 mill

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye